MiniMed IPO Targets $7.86B Valuation as Medtronic Spins Off Diabetes Unit

MiniMed Group is preparing to enter the public market as an independent diabetes technology company, with its planned U.S. initial public offering targeting a valuation of as much as $7.86 billion. The business, which is being separated from medical device giant Medtronic, is expected to raise up to $784 million by selling 28 million shares priced between $25 and $28. Once listed, the company intends to trade on the Nasdaq under the ticker MMED.

The IPO marks one of Medtronic’s biggest corporate changes in recent years. Instead of operating as one division inside a global healthcare company, MiniMed will become a standalone business focused entirely on insulin pumps, continuous glucose monitoring technology, and diabetes management systems.

Medtronic moves ahead with long-planned separation

Medtronic announced its intention to separate the diabetes business as part of a broader strategy to simplify its portfolio and concentrate investment on larger business segments, including cardiovascular, neuroscience, and surgical technologies.

The IPO represents the first stage of that plan. Medtronic has indicated it expects to complete a full split-off roughly six months after the public listing, allowing MiniMed to operate independently with its own leadership team, financial reporting, and long-term growth strategy.

The move reflects a wider trend across the medical technology industry, where diversified companies are increasingly separating specialized businesses so investors can evaluate them on their own financial performance.

Established diabetes business enters a new chapter

Unlike many companies entering the IPO market, MiniMed already has a long operating history. The diabetes business has manufactured insulin pumps for more than 40 years and became part of Medtronic through an acquisition valued at nearly $3.3 billion around 25 years ago.

Today, the company generates revenue from insulin pump systems, glucose sensors, infusion sets, and other diabetes-related products used by patients around the world. Those recurring product sales provide a steady source of income beyond initial device purchases.

The company’s latest product lineup, including the MiniMed 780G automated insulin delivery system, has helped strengthen sales growth as more patients adopt advanced diabetes management technology.

Profitability remains a key question

Although MiniMed has continued expanding its product portfolio, the company has reported net losses during each of the past three years. As an independent public company, investors are expected to pay close attention to whether revenue growth can translate into stronger earnings and improved cash flow.

The separation also means MiniMed will no longer rely on Medtronic’s broader financial resources. Instead, management will need to demonstrate consistent execution, cost discipline, and progress toward sustainable profitability.

Regulatory compliance will remain another important focus. The diabetes business has previously worked through quality system improvements and cybersecurity-related matters affecting certain products, making future regulatory performance an area closely watched by institutional investors.

Competition in diabetes technology continues to grow

The global diabetes device market has become increasingly competitive as manufacturers race to improve automated insulin delivery, sensor accuracy, and ease of use. Companies are investing heavily in technologies that reduce manual intervention while giving patients better glucose control.

MiniMed enters the market with an established customer base, but it will compete against businesses that continue launching new continuous glucose monitoring systems and integrated diabetes platforms. Maintaining product innovation while protecting profit margins will likely become one of its biggest long-term challenges.

Healthcare investors following medical device IPOs may compare MiniMed’s performance with other established diabetes technology companies as the business begins reporting standalone financial results.

IPO could become an important test for the broader market

The offering arrives as investor appetite for new public listings has gradually improved, although buyers remain selective. Businesses with established revenue streams have generally attracted stronger interest than early-stage companies with uncertain financial outlooks.

MiniMed’s targeted valuation suggests investors see long-term demand for diabetes care technology, but future share performance will depend on more than its IPO price. Revenue growth, operating margins, product launches, and execution after the separation will likely have the greatest influence on market confidence.

For investors tracking healthcare listings, the transaction could provide insight into how the public market values focused medical device companies compared with larger diversified manufacturers. Those following the broader sector may also find developments in the weight-loss drug market relevant, particularly as companies continue investing in diabetes care innovation alongside obesity treatments. For additional industry context, see our coverage of Novo Nordisk’s planned U.S. price cuts for Ozempic and Wegovy.